Browse investments

Invest in MapLight Therapeutics, Inc. on Stash

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS).

To buy fractional shares of MapLight Therapeutics, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: MPLT

MapLight Therapeutics, Inc.

$39.80

+16.03%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by LSEG Data & Analytics in partnership with: LSEG FX in collaboration with: LSEG Risk Intelligence. Stash cannot and does not represent or guarantee that any of the information available via LSEG Data & Analytics is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

MPLT Performance Breakdown

Share Price

$39.80

Today's change

3.3%

Year to date change (YTD)

137.33%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About MPLT

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.

MapLight Therapeutics, Inc. Stock Ticker

MPLT

For more information

maplightrx.com

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by LSEG Data & Analytics in partnership with: LSEG FX in collaboration with: LSEG Risk Intelligence. Stash cannot and does not represent or guarantee that any of the information available via LSEG Data & Analytics is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in MapLight Therapeutics, Inc. on Stash

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS).

To buy fractional shares of MapLight Therapeutics, Inc. stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

MapLight Therapeutics, Inc. stock news

24/7 Wall Street

Micron, SanDisk, and Western Digital Sink 7% as Samsung Earnings Spark a Memory Selloff

Memory and storage stocks are selling off sharply in early trading Tuesday, reversing Monday's rebound.

2 days ago

CNBC

Amazon raising at least $25 billion in bond sale, won't issue more debt in 2026

Amazon plans to raise at least $25 billion through a bond sale, sources told CNBC's David Faber. It marks the company's latest debt raise as it looks to buttress its massive investments in artificial intelligence.

2 days ago

Business Insider

One robotaxi player has grown its share of users so far in 2026 — and it's not Waymo

Alphabet-owned Waymo has long had a size and time advantage in the robotaxi world. A new report shows Amazon-owned rival Zoox gaining users, though.

2 days ago

24/7 Wall Street

Walmart Drops The Price Of Coke By 33%

Walmart (NYSE: WMT | WMT Price Prediction) announced it is dropping prices on thousands of items it sells in its stores.

2 days ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy MapLight Therapeutics, Inc. stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

MapLight Therapeutics, Inc.’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. MapLight Therapeutics, Inc.’s price can fluctuate throughout the course of each trading day—when you buy MapLight Therapeutics, Inc. through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time MapLight Therapeutics, Inc. stock price and the MapLight Therapeutics, Inc. news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers one subscription plan: The Stash Plan.

The Stash Plan can help you reach different goals and offers a unique combination of financial accounts and features. This plan includes access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of MapLight Therapeutics, Inc. stock is complete, you'll officially be a shareholder of MapLight Therapeutics, Inc.!